Balance Sheet
Cash Flow Statement
AmortizationAmortization of Deferred ChargesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital Changes
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioLineRx (BLRX) Cash from Financing Activities (2023 - 2025)

Historic Cash from Financing Activities for BioLineRx (BLRX) over the last 3 years, with Q3 2025 value amounting to -$916000.0.

  • BioLineRx's Cash from Financing Activities rose 2479.47% to -$916000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $9.0 million, marking a year-over-year decrease of 7305.94%. This contributed to the annual value of $20.7 million for FY2024, which is 3720.78% up from last year.
  • Per BioLineRx's latest filing, its Cash from Financing Activities stood at -$916000.0 for Q3 2025, which was up 2479.47% from $1.6 million recorded in Q2 2025.
  • In the past 5 years, BioLineRx's Cash from Financing Activities ranged from a high of $23.9 million in Q2 2024 and a low of -$1.2 million during Q3 2024
  • In the last 3 years, BioLineRx's Cash from Financing Activities had a median value of -$49000.0 in 2023 and averaged $4.2 million.
  • Data for BioLineRx's Cash from Financing Activities shows a peak YoY increase of 1792014.93% (in 2024) and a maximum YoY decrease of 172448.98% (in 2024) over the last 5 years.
  • Quarter analysis of 3 years shows BioLineRx's Cash from Financing Activities stood at $11.7 million in 2023, then tumbled by 109.45% to -$1.1 million in 2024, then increased by 17.4% to -$916000.0 in 2025.
  • Its last three reported values are -$916000.0 in Q3 2025, $1.6 million for Q2 2025, and $9.4 million during Q1 2025.